

Bibliography

Literature

A. Merrill, Stephen. (2004) *A Patent System for 21st Century*. Washington, D.C: National Academic Press.

Balance, et all. (1992). *The World's Pharmaceutical Industry: An International Comparative Study*. United States of America: Edward Elgar.

Barfield, Claude. (2007). *Biotechnology and The Patent System: Balancing Innovation and Property Rights*. Washington D. C: American Enterprises Institute.

India Ministry of Commerce and Industry. (2016). *National Intellectual Property Rights Policy*. New Delhi: Department of Industrial Policy and Promotion.

Joseph, Reji. (2011). *The R&D Scenario in India Pharmaceutical Industry*. New Delhi: Research and Information System for Developing Countries – India Ministry of External Affairs.

Khanta, Sharmila. (2006). *Building India with Partnership: The Story of CII 1885-2005*. New Delhi: Penguin.

Kirton J. John et all. (2014) *Moving Health Sovereignty in Africa*. New York: Routledg.

Lippert, Owen. (1999). *Competitive Strategies for The Protection of Intellectual Property Rights*. Canada: The Frasher Institute.

Malhotra, Prabodh. (2010). *Impact on TRIPS in India: An Access to Medicine Perspective*. United Kingdom: Palgrave MacMillan.

Muzaka, Valbona. (2010). *The Politics of IPR and Access to Medicine*. United Kingdom: Palgrave MacMillan.

Ostry, Sylvia. (1999). *Intellectual Property Protection in WTO – TRIPS Built-In Agenda: Generic Issue*. Canada: The Fraser Institute.

Rana. S, Kishan. (2000). *Inside Diplomacy*. New Delhi: Manas Publication.

Sell. K, Susan. (2003). *Private Power Public Law: The Globalization of Intellectual Property Rights*. United States of America: Cambridge University Press.

Sikri, Rajiv. (2013) *Challenge and Strategy: Rethinking India Foreign Policy*. New Delhi: Sage Publications.



Singh Kumar, Kshitji. (2015). *Biotechnology and IPR: Legal and Social Implication*. New Delhi: Springer.

T. Hoen, Ellen. (2009). *The Global Politics of Pharmaceutical Power*. Netherland: AMB Publisher.

United Nation Conference on Trade and Development. (2010). *Intellectual Property In The World Trade Organization: Turning It Into Developing Countries' Real Property*. Geneva: United Nation Publications

World Intellectual Property Organization (2012). *The Enforcement of Intellectual Property Rights: A Case Book*. Geneva: WIPO Publications.

Journal

Chander, Harris et all. (2013). Current Scenario of Patent Act: Compulsory License. *Indian Journal of Pharmaceutical Education and Research*, 47(3), 26-29. doi: http://www.ijper.org/sites/default/files/ijper_47_3_5.pdf

Chun, Dongwook. (2011). Patent Law Harmonization In The Age of Globalization: The Necessity and Strategy for a Pragmatic Outcome. *Cornell Law School Inter-University Graduate Conference Papers*, 4(1), 1-51. doi:<http://scholarship.law.cornell.edu/>

Ghai, Damanjeet. (2010). Patent Protection and India Pharmaceutical Industry. *International Journal of Pharmaceutical Science Review and Research*, 3(2), 43 -48. doi:<http://www.globalresearchonline.net/>

Kapczynski, Amy. (2009). Harmonization and Its Discontents: A Case Study of TRIPS Implementation in India's Pharmaceutical Sector. *California Law Review*, 97(6), 1571 – 1649. doi: <http://scholarship.law.berkeley.edu/>

Mazolleni, Robert., R. Nelson, Richard. (1998). Economic Theories and about The Benefit and Cost of Patents. *Journal of Economic Issue*, 32, 1031 – 1033. doi: <https://www.bc.edu/~zlate/biotech/mazzolininelson1998.pdf>

Murthy Divya. (2002) The Future of Compulsory License: Deciphering The Doha Agreement on TRIPS and Public Health. *American University International Law Review*, 17(6), 1-49. doi: <http://digitalcommons.wcl.american.edu/>

Subhan, Junaid. (2006). Scrutinized: The TRIPS Agreement and Public Health. *Mc Gill Journal of Medicine*, 9(2), 152-159. doi: <https://www.ncbi.nlm.nih.gov/>



Varun Vaish and Mustafa Haji. (2012). Is There a Need to “Substantially Modify” The Terms in TRIPS Agreement?. *Journal of Intellectual Property Rights*, 12, 195 - 208. doi: <https://papers.ssrn.com/>

Watal, Jayashree. (1999). Introducing Patent Products in The Indian Pharmaceutical Sectors: Implication for Prices and Welfare. *World Competition*, 20, 5-21. doi: <https://www.iatp.org/>

Periodical Publication

Chaudhuri et all. (2003). *The Effect of Extending Intellectual Property Protection in Developing Countries: A Case Study of India Pharmaceutical Market* [Monograph]. Retrieved from <https://academiccommons.columbia.edu/catalog/ac%3A116003>

Ezparza, Javier. (2015). *Indian Patent Law: Working Within The TRIPS Agreement Flexibilities To Provide Pharmaceutical Patents While Protecting Public Health* [Monograph]. Retrieved from <https://www.mcgeorge.edu>

International Center for Trade and Sustainable Development. (2007). *Rwanda Becomes The First Country to Try to Use WTO Procedure to Imported HIV/AIDS Drugs* [Monograph]. Retrieved from <http://www.ictsd.org/>

Mercurio C., Brian. (2004). *TRIPS, Patent, and Access to Life –Saving Drugs in Developing Countries* [Monograph]. Retrieved from <https://papers.ssrn.com/>

Rana, S. Kishan. *Economic Diplomacy: The Experience of Developing Countries*. [Monograph]. Retrieved from <http://www.cuts-citee.org/>

Unni, V.K. (2012). *India Patent Law and TRIPS: Redrawing The Flexibility Framework in The Context of Public Policy and Health*. [Monograph]. Retrieved from <http://scholarlycommons.pacific.edu/>

Law Case

Novartis AG v. Union of India., 2706 – 2716. (2013). Retrieved from <http://judis.nic.in/supremecourt/>

Website

“The Future of Generic Medicine Made in India”. *Medecins Sans Frontier*. Medecins Sans Frontiers, 21 April. 2005. Web.29 Juli. 2016.

Babu, Gireesh. (2015, Oct 8). Q&A: We Want Transparent, Efficient, and Predictable Regime. *Business Standard*. Retrieved from <http://www.business-standard.com/>



Bay of Bengal Initiative for Multi – Sectoral Technical and Economic Cooperation. *Background of BIMST EC*. Retrieved from <http://www.bimstec.org/>

Compulsory License, Sec. 84, India Patent Act. (1970). Retrieved from <https://indiankanoon.org/doc/799603/>

Compulsory License, Sec. 92, India Patent Act (1970). Retrieved from <https://indiankanoon.org/doc/986301/>

Dey, Sushmi. (2014, May 20). News: Domestic Pharma to Lobby Modi Govt. *Business Standard*. Retrieved from <http://www.business-standard.com/>

Editorial Team. (2014, Nov 6). Article: Bangladesh Holds Huge Potential for India Pharma. *Pharmabiz*. Retrieved from <http://www.pharmabiz.com/>

Editorial Team. (2016, Feb 2). News: India Sun Pharma's launches Generic Version of Novartis's Glivec in the USA. *The Pharma Letter*. Retrieved from <http://www.thepharmaletter.com/>

Euromoney Institutional Investor Companies. (2014). *Pharmaceutical Sector Brazil*. Retrieved from <https://www.emis.com/>

Hyderabad, A. Raju. (2014, Nov 6). Article: Generic Drugs Demand Grows in South Asia and Africa. *Pharmabiz*. Retrieved from <http://www.pharmabiz.com/>

IBSA Trilateral. *About IBSA – Introduction*. Retrieved from <http://www.ibsa-trilateral.org/index.php>

Indian Pharmaceutical Associations. (2016). *Welcome to India Pharmaceutical Association*. Retrieved from <http://www.ipapharma.org/>

Jishnu, Latha. (2008, Mei 29). Article: Thailand Banks on India for Generic Drugs. *Business Standard*. Retrieved from <http://www.business-standard.com/>

Krishna, Jai. (2013, April 1). Article: Novartis Loses Glivec Patent Battle in India. *Wall Street Journal*. Retrieved from <http://www.wsj.com/>

Lexology. (2014). *Section 3 (d) of India Patent Act 1970: Significance and Interpretation*. Retrieved from <http://www.lexology.com/library/>

Malson, Gareth. (2009, Des 14). Opinion: Ever Wondered Whether Owning Your Own Pharmacy Is Worth It?. *Pharmaceutical Journal*. Retrieved <http://www.pharmaceutical-journal.com/>



Medecins Sans Frontier. (2005, April 21). News: The Future of Generic Medicine in India. *Medecins Sans Frontier*. Retrieved from <http://www.msf.org/>

Medecins Sans Frontier. (2012). *Q&A: Patent in India and The Novartis Case*. Retrieved from <http://www.msf.org/>.

Medecins Sans Frontier. (2016, Mar 1). News: MSF Challenge Pfizer's Attempt to Patent Pneumonia Vaccine in India. *Medecins Sans Frontier*. Retrieved from <http://www.msf.org/>.

Nandkumar, Anad. (2011, Okt 18). Article: Was The TRIPS Worthwhile?. *Forbes India Magazine*. Retrieved from <http://www.forbesindia.com/>

Novartis Oncology. (2016), *Glivec*. Retrieved from <https://www.novartisoncology.com/>

Pant, Rashmi. (2016, Jan 6). Article: Indian Pharmaceutical Export: The Growth Story. *Business Standard*. Retrieved from <http://www.business-standard.com/>

Pharmaceutical Export Council. (2010). *Pharmaceutical Sector in Myanmar*. Retrieved from <http://www.pharmexcil.com/>

Pharmaceutical Export Council. (2013). *Opportunity – African Market for Indian Companies*. Retrieved from <http://www.unido.org/>

Press Trust of India. (2014, June 27). News: Consequences if India Fails to Act on IPR, Warns US Lawaker. *Business Standard*. Retrieved from <http://www.business-standard.com/>

Saez, Catherine. (2016, Nov 6). News: Indian Generic Pharma Warns Against Government Caving to US Pressure on Data Exclusivity. *IP Watch Organization*. Retrieved from <http://www.ip-watch.org/>

Sec. 3 (d), Invention Not Patentable, India Patent Act. (2005). Retrieved from <http://www.ip-watch.org/>

Sharma, Kumar E. (2015, Feb 1). News: Hard Bargaining Ahead. *Business Today*. Retrieved from <http://www.businesstoday.in/>

Sun Pharma Sri Lanka. *Establishment and Growth*. Retrieved from <http://www.sunpharma.com/>

The Editorial Board. (2013, April 4). Opinion: India's Novartis Decision. *New York Times*. Retrieved from <http://www.nytimes.com/>



The Pharma Letter. (2015). *India – Africa Summit Focus on Generic and Indian Investment in Africa*. Retrieved from <http://www.thepharmaletter.com/>

World Trade Organization. (2001). *Doha Declaration on TRIPS Agreement and Public Health*. Retrieved from <https://www.wto.org/>

World Trade Organization. (2006). *Pharmaceutical Patents and TRIPS Agreement*. Retrieved from <https://www.wto.org/>

World Trade Organization. (2016). *Part II – Standard Concerning The Availability, Scope, and The Use of IPR, Section 5 - Patent, Article 27 – Patentable Subject Matter*. Retrieved from <https://www.wto.org/>

World Trade Organization. (2016). *TRIPS and Pharmaceutical Patents - Obligation and Exception*. Retrieved from <https://www.wto.org/>